Edition:
United Kingdom

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

123.91USD
19 Jan 2018
Change (% chg)

$2.19 (+1.80%)
Prev Close
$121.72
Open
$122.05
Day's High
$124.05
Day's Low
$121.99
Volume
469,423
Avg. Vol
370,679
52-wk High
$124.05
52-wk Low
$86.55

Select another date:

Wed, Dec 6 2017

BRIEF-Edwards Lifesciences Corp Acquires Harpoon Medical

* EDWARDS LIFESCIENCES CORP - EDWARDS PAID $100 MILLION IN CASH FOR HARPOON AT CLOSING ON DEC. 1

Edwards results fall short of Street estimates; shares tumble

Edwards Lifesciences Corp on Tuesday reported slightly lower-than-expected third-quarter profit and revenue and saw a dip in sales of its critically important transcatheter heart valves from the prior quarter, although they grew about 17 percent from a year earlier.

UPDATE 1-Edwards results fall short of Street estimates; shares tumble

Oct 24 Edwards Lifesciences Corp on Tuesday reported slightly lower-than-expected third-quarter profit and revenue and saw a dip in sales of its critically important transcatheter heart valves from the prior quarter, although they grew about 17 percent from a year earlier.

Edwards 3rd-quarter results short of Street estimates; shares fall

Oct 24 Edwards Lifesciences Corp on Tuesday reported slightly lower-than-expected third-quarter profit and revenue and saw a dip in sales of its critically important transcatheter heart valves from the prior quarter, although they grew about 17 percent from a year earlier.

Edwards Lifesciences raises 2017 forecast after strong quarter

Edwards Lifesciences Corp on Wednesday provided a revised full-year earnings forecast with the new low end of the range above Wall Street estimates, and it posted higher-than-expected second-quarter profit on double-digit growth in sales of its transcatheter heart valves.

UPDATE 2-Edwards Lifesciences raises 2017 forecast after strong quarter

July 26 Edwards Lifesciences Corp on Wednesday provided a revised full-year earnings forecast with the new low end of the range above Wall Street estimates, and it posted higher-than-expected second-quarter profit on double-digit growth in sales of its transcatheter heart valves.

Edwards Lifesciences raises 2017 forecast after strong quarter

July 26 Edwards Lifesciences Corp on Wednesday provided a revised full-year earnings forecast with the new low end of the range above Wall Street estimates, and it posted higher-than-expected second-quarter profit on double-digit growth in sales of its transcatheter heart valve replacements.

Select another date: